SARTF:OTC-Sartorius Aktiengesellschaft (USD)

COMMON STOCK | | OTC

Last Closing Price

USD 420.00

Change

0.00 (0.00)%

Market Cap

USD 33.41B

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Sartorius Aktiengesellschaft supplies pharmaceutical and laboratory equipment worldwide. It operates in two divisions, Bioprocess Solutions, and Lab Products & Services. The company offers live cell analysis system, and cell analysis reagents and consumables; cell culture media, including antibody and recombinant protein, viral vaccines, and regenerative medicine media; and multi-parallel, single-use, benchtop, stainless steel, microbial, and cell culture bioreactors, as well as cell culture expansion systems and software applications for bioreactors. It also provides lab filtration and purification devices; sterile and virus filtration, crossflow filtration, harvesting, prefiltration, membrane chromatography, air/gas filtration, and integrity testing devices; and liquid storage and shipping, freeze and thaw, mixing, proven integrity, transferring and sampling, connecting and disconnecting, and final filling management products. In addition, the company offers process control and data analytics products, such as process analyzers, automation modules, and data analytics and chemometrics; and microbiology products, and lab water purification systems. Further, it provides lab balances, mass comparators and metrology, moisture analyzers, specialty weighing solutions, weighing accessories, weights/weight sets, paint mixing solutions, and OEM weigh cells; and OEM membrane and device, pipetting and dispensing, and connectivity solutions. Additionally, the company offers bioprocess development engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, cannabis testing, food and beverage, environmental, and paint mixing industries. Sartorius Aktiengesellschaft and Evotec SE has a partnership with Curexsys GmbH on iPSC-based therapeutic exosome approach. The company was founded in 1870 and is headquartered in Göttingen, Germany.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-23 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BTHI Big Time Holdings, Inc

N/A

USD151.65B N/A N/A
WXIBF WuXi Biologics (Cayman) Inc

N/A

USD65.43B 350.00 39.96
DFIFF Diamond Fields Resources Inc

N/A

USD60.08B 39.43 N/A
SEMHF Siemens Healthineers AG

N/A

USD54.04B 37.26 N/A
HENOF Henkel AG & Co. KGaA

N/A

USD44.44B 15.98 N/A
HDALF Haidilao International Holding..

N/A

USD43.75B 79.20 12.68
YACAF Yancoal Australia Ltd

N/A

USD41.57B 0.20 N/A
MQBKY Macquarie Group Limited

N/A

USD38.29B 23.01 8.72
PETFF PTT Public Company Limited

N/A

USD34.53B 14.15 0.17
CRHKF China Resources Beer (Holdings..

N/A

USD32.56B 95.80 N/A

ETFs Containing SARTF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification ()
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 81.82% N/A N/A 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 81.82% N/A N/A 73% C
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 37.01% N/A N/A 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 37.01% N/A N/A 74% C
Risk Return Profile  
Volatility (Standard Deviation) 54.21% N/A N/A 40% F
Risk Adjusted Return 68.28% N/A N/A 92% A-
Market Capitalization 33.41B N/A N/A 96% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
()
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 114.64 N/A N/A 6% F
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio 88.59 N/A N/A 3% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity 22.72% N/A N/A 92% A-
Return on Invested Capital 15.75% N/A N/A 79% C+
Return on Assets 7.96% N/A N/A 92% A-
Debt to Equity Ratio 101.45% N/A N/A 18% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.32 N/A N/A 74% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:

There is nothing we particularly dislike